CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2010-09-24): Body fat distribution influences liver fibrosis

Epidemiology

Body fat distribution influences liver fibrosis

Last Updated: 2010-09-24 12:45:12 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Fibrosis stage in nonalcoholic fatty liver disease is linked with how much peripheral and abdominal fat a patient has, researchers have found.

Even after adjustment for other factors, "liver fibrosis was significantly associated with regional body sizes -- the extremities and abdomen -- in a gender- and menopausal-specific manner," lead author Dr. Ayako Suzuki told Reuters Health by email.

Dr. Suzuki of Duke University, Durham, North Carolina, and colleagues report in an August 23rd online paper in Clinical Gastroenterology and Hepatology on a cross-sectional analysis of regional anthropomorphic measures in 537 patients. Their mean age was 48 years; their mean body mass index - 34.6 -- was in the obese range.

The authors defined peripheral adipose depot size (extremity size) as the sum of z-scores of the middle upper arm circumference and hip circumference, relative to total body size. They defined abdominal adipose depot size as waist circumference.

The prevalence of advanced fibrosis (stage 3 or 4) varied significantly and was highest in postmenopausal women (36.1%). For men, the prevalence was 17.7 % and for pre-menopausal women, it was 13.5%.

Furthermore, men with smaller extremity size (i.e., with larger abdominal girth), pre-menopausal women with larger extremity size, and post-menopausal women with larger abdominal size were more likely to have higher stages of fibrosis. This was after adjustment for caloric intake and energy expenditure.

"This implies that body fat distribution in conjunction with gender- and menopause-associated factors may impact the disease severity of nonalcoholic fatty liver disease," Dr. Suzuki said.

"A better understanding of underlying mechanisms warrants further investigation," she concluded, "as this may allow for a 'tailored' patient-specific treatment plan for those with nonalcoholic fatty liver disease in the future."

SOURCE: http://link.reuters.com/pav35p

Clin Gastroenterol Hepatol 2010.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.